RAC 0.97% $1.54 race oncology ltd

Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-175

  1. 209 Posts.
    lightbulb Created with Sketch. 112
    To anyone new to Race and also some sceptical investors, I would suggest to LISTEN to the MST interview in full, but especially around 33 minutes onwards. Both PS and DT explain very clearly their view and the future, some of it is within a rather short time frame especially from a biotech's point of view. I listened to that section several time and every time it just getting better for me. This interview maybe the best I ever heard from Race. The link was already posted by Teeth and also Dr Tillett but here it is again.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.